Anyone else in Renovo?

49p of cash, trading at 35p.

If Juvista is approved later this year then license fee of $825m in the bank
(approx 7 x current share price)

Rest of the pipeline thrown in for nothing...

Andy, I just hope they dont go 'tits up'.

I think youl get my drift, im sure.

cheers GF.

I reckon is worth 40p gf do you still hold..?

Nope mitzy.

Moving ahead maybe 30p later today.

Cash in the bank is worth 60p so 40p could well be possible.

The directors of Biocompatibles (LSE: BII), Silence Therapeutics (AIM: SLN), Renovo Group Plc (LSE: RNVO) and smartFOCUS Group (AIM: STF) will be presenting:
Thursday the 9th September 2010, Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapand wine reception. Details on the presenting companies can be found below.

This event is suitable for the following:
Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.

Register here - http://www.proactiveinvestors.co.uk/register/event_details/87

If you have any problems registering or queries please email events@proactiveinvestors.com.

i was wondering why this was reversing today - i hope people did not get too burnt and lost only profit

was considering rnvo myself but after being tipped in the nationals left it after steep rises - sorry to any who lost here - very bad luck

imo this is way over done - dont they have cash in the bank worth at least 50p and other projects - i am in now! gla

a wave of blue lol!

dont forget:
Adaprev Reduction of adhesions following digital tendon injury Class III medical device in the EU.
Prevascar Reduction of skin scarring Phase 2

Juvidex Improve skin appearance and promote healing of damaged skin Cosmetic ingredient out-license

Adaprev Reduction of adhesions following digital tendon injury Class III medical device in the EU. Safety and preliminary performance (first of 2 trials for approval)

Prevascar Reduction of skin scarring Phase 2 - H1 2011 Proof of efficacy trial in
Juvidex Improve skin appearance and promote healing of damaged skin Cosmetic ingredient
&
RN1005
& cash in bank

yep they do have cash....

During the period the Company has continued to expend its cash balances developing its product portfolio. Renovos
combination of cash and cash equivalents with term deposits maturing within one year as at 31 December 2010 was
46.1 million, compared to the 51.8 million previously reported as at 30 September 2010. Renovos management
team believes that the Company is appropriately funded for continuing ongoing operations. As previously reported,
the net cash position, including investments, at the time of reporting the first Juvista EU Phase 3 trial in H1 2011 is
expected to be at least 30 million.

bouncing i believe!

Not another ASM

its going up - still cheap for now!!!!

18p is below cash. 40m

driver -hello dude - yep 18p is below cash and they have other projects - may also make them a t/o target - now it has got interesting gonna find out more over the weekend - i so nearly invested here but the darn newspaper report sent it skying and imo didnt leave enough margin for me - however made a little beer money here today and will watch closely monday - real shock to see rnvo tank - when i saw it i thought it must be an error but it werent, feel for any caught - personally hoping for a rebound anywhere in the 20 to 30p range then of course results of other trials as they come in - gl

bayliss - that is one grim chart!!

Renovo shares plunge after Juvista trial failure


Shares in biopharma company Renovo Group plc dropped sharply after it announced the failure of its key Juvista scar-healing product in Phase III trials.

Renovo said the first EU Phase III trial for Juvista in scar revision surgery did not meet its primary or secondary endpoints.

The company would conduct further exploratory analysis and determine the future of the Juvista development programme.

CEO Professor Mark Ferguson said, 'We are extremely surprised and disappointed by the failure of Juvista to meet the Phase III trial primary and secondary endpoints.

'The board of Renovo will now consider all options open to it to maximise shareholder value.'

Shares were down to 17p at close.

hlyeo - yep - word is current cash is about 23-25p : i may well buy back in here monday from what i have heard:
1/ rnvo will continue and see if it is feasible to continue with juvista at all - major set back - however i would expect not due to the costs of continuing and the costs of the other trials due h1 2011
2/ Shire the jv have invested around 80M to date with rnvo and in fact there are whispers that Shire may t/o rnvo - i would like that if i can get in cheap enough again!!!
3/ rnvo will be wound up and cash back to share holders - which seems pretty good option also

all this should be decided pretty quickly - no more than 3 months imo

gla